SAN DIEGO, May 17, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m.
ET/11:30 a.m. PT. Laurie Stelzer, chief financial
officer, will provide a corporate overview.
The presentation will be webcast through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live
webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any
necessary audio software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies
that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique
approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is
headquartered in San Diego. For more information visit www.halozyme.com.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-ubs-2016-global-health-care-conference-300270315.html
SOURCE Halozyme Therapeutics, Inc.